Scientists test RSV shot in most vulnerable elderly
NCT ID NCT07203365
Summary
This study is testing how well the approved RSV vaccine Arexvy works in adults aged 80 and older compared to those aged 60-65. Researchers want to see if the vaccine produces a strong immune response in the most elderly and frail populations, who are at highest risk for severe RSV illness. The study will measure antibody levels and monitor safety in about 65 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RSV IMMUNISATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Akademiskt specialistcentrum Studieenheten
RECRUITINGStockholm, 113 61, Sweden
Contact Email: •••••@•••••
-
Familjeläkarna SÄBO
RECRUITINGSaltsjöbaden, 13334, Sweden
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.